Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934698 | 0.98 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21065340 | 0.91 | CA12 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9990414 | 0.87 | SMN1; SMN2 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| Cyclohexanol SCHEMBL9499967 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| Cyclohexanol SCHEMBL9497715 | 0.86 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2755862 | 0.85 | RAD52 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL9990508 | 0.85 | SMN1; SMN2 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18824247 | 0.85 | HDAC2 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL7068538 | 0.84 | RAD52 (0.55) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL4069459 | 0.83 | HSD17B10 (0.54) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| US-11130750-B2 | Calcium channel inhibitors | CAVION, INC. (US) | 2021-09-28 | — | — | US | claimed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | claimed |
| EP-3296313-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO LTD (CN) | 2020-12-16 | — | — | EP | claimed |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CAVION, INC. | 2020-12-10 | — | — | US | claimed |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | claimed |
| EP-3453714-B1 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | SUZHOU NEUPHARMA CO LTD (CN) | 2020-11-04 | — | — | EP | claimed |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-08 | — | — | US | claimed |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-01-23 | — | — | US | claimed |
| CN-104080335-A | Certain chemical entities, compositions, and methods | QIAN XIANGPING | 2014-10-01 | — | — | CN | claimed |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-05-15 | — | — | US | claimed |
| CN-102203112-B | Certain compounds, compositions and methods | SUZHOU NEUPHARMA CO LTD | 2014-05-07 | — | — | CN | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| EP-2699557-A1 | AROMATIC AMIDES AND USES THEREOF | Biota Scientific Management Pty Ltd (AU) | 2014-02-26 | — | — | EP | claimed |
| US-8614211-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2013-12-24 | — | — | US | claimed |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2013-02-14 | — | — | US | claimed |
| WO-2013023145-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-02-14 | — | — | WO | claimed |
| WO-2012142671-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-10-26 | — | — | WO | claimed |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2012-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130750-B2 | Calcium channel inhibitors | CACNA1F, ORAI1, CACNA1E | CA12 1400/4885CA1 391/4885CA2 82/4885 |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | CA12 271/4885CA1 2558/4885CA2 1540/4885 |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | UGT2B7, BCCIP, ABCG2 | CA12 941/4885CA1 2824/4885CA2 1613/4885 |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | CA12 271/4885CA1 2558/4885CA2 1540/4885 |
| US-20200385367-A1 | CALCIUM CHANNEL INHIBITORS | CACNA1F, ORAI1, CACNA1E | CA12 1400/4885CA1 391/4885CA2 82/4885 |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | CA12 271/4885CA1 2558/4885CA2 1540/4885 |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | CA12 271/4885CA1 2558/4885CA2 1540/4885 |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | CA12 941/4885CA1 2824/4885CA2 1613/4885 |
| US-20130040945-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RXRG, ARNT, RARS2 | CA12 986/4885CA1 2686/4885CA2 2121/4885 |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | NAT1, ASNS, CYP2C9 | CA12 2766/4885CA1 1695/4885CA2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.